SIEMENS HEALTHCARE DIAGNOSTICS, INC. ADVIA CENTAUR SARS-COV-2 TOTAL (COV2T); SARS-COV-2 IMMUNOASSAY
|
Back to Search Results |
|
Model Number N/A |
Device Problem
False Positive Result (1227)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 11/23/2020 |
Event Type
malfunction
|
Manufacturer Narrative
|
Siemens has been on site and performed several total service calls on the instrument.The system was decontaminated.Siemens continues to investigate.The limitations section of the instructions for use states: "this assay should not be used to diagnose or exclude acute infection.Results are not intended to be used as the sole basis for patient management decisions.Test results should be interpreted in conjunction with clinical observations, patient history, epidemiological information, and other laboratory findings.A reactive test result does not exclude past or present infection by other coronaviruses, such as sars-cov-1, mers-cov, hku1, 229e, nl63, or oc43." a false positive/reactive result would not be used in isolation and would be correlated with clinical history.Additional laboratory testing would be used to determine specific antibody presence.Although there is no potential for serious injury in this case, an mdr will be reported to the fda as a requirement of the emergency use authorization (eua).
|
|
Event Description
|
The customer observed a reactive (positive) advia centaur xp sars-cov-2 total (cov2t) result for 1 patient which was considered discordant to two other nonreactive (negative) replicates.The customer did not report the reactive (positive) result.There are no reports of patient intervention or adverse health consequences due to the discordant cov2t result.
|
|
Manufacturer Narrative
|
Mdr 1219913-2020-00639 was filed on december 16, 2020.Additional information january 21, 2021: a full review of the system has been performed.No major issues were identified.A review of the customer's data indicates a 1.07% frequency of discordant results.Internally, a frequency of 1.22% discordant results was obtained with lot 003.Siemens continues to investigate the report.
|
|
Manufacturer Narrative
|
Mdr 1219913-2020-00639 was filed on december 16, 2020 and mdr 1219913-2020-00639 supplemental 1 was filed on february 11, 2021.Additional information february 11, 2021: the account observed non-reproducible reactive results with advia centaur xp sars-cov-2 total lot 709003.Siemens performed hardware troubleshooting and also performed preventative maintenance.No major issues were found.Cov2t lot 709003 was included in testing performed as part of the investigation for atellica im and advia centaur sars-cov-2 total (cov2t) non-reproducible false reactive results with lots 709004, 709005, 709006, 709035.Cov2t lot 709003 variability and discordant frequency is 1.22% compared to 3.37% for cov2t lots 709005/709035.The rate of incidence at the account is approximately 1.07%.Based on the information provided, no product non-conformance was identified.Cov2t lot 709003 is meeting assay claims.Customer is operational.No further action is needed.
|
|
Search Alerts/Recalls
|
|
|